Please login to the form below

Not currently logged in
Email:
Password:

Alnylam teams with Isis on joint startup

Alnylam forms jv company with Isis to commercialise microRNA-derived (miRN) drugs in the US

US-based Alnylam Pharmaceuticals has formed a joint venture (jv) company, Regulus Therapeutics, with Isis Pharmaceuticals to commercialise microRNA-derived (miRN) drugs in the US.

Regulus will combine technologies from Alnylam and Isis Pharmaceuticals to create the jv, which will be controlled by a separate management team, board of directors and scientific advisory board. The new firm will be chaired by Nobel prize winner, David Baltimore.

Alnylam added that the company will make an initial investment of USD 10m in Regulus, and will share future funding of the venture with Isis. Both Alnylam and Isis have granted the new company exclusive licenses to miRNA technology of Isis and Alnylam.

MiRN drugs are expected to be able to regulate multiple human genes with potential to treat a number of presently unmet medical needs.

Alnylam develops drugs which implement RNA-interference (RNAi) technology that works by switching off damaged or lethal genes thereby treating diseases. Alnylam reported a FY06 net loss of USD 34.6m on sales of USD 26.9m.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics